TEVA Pharmaceutical Industries issued $1,200,000,000 in 5.250% USD senior notes due 2032 and multiple Euro and USD note tranches on September 16, 2026. The proceeds will fund redemptions of existing notes, related fees and expenses, and remaining amounts will support general corporate purposes, including Debt repayment.

Key Highlights

  • The new notes carry maturities ranging from 2032 through 2037, with USD coupons between 5.250% and 5.750%.
  • Teva intends to use the proceeds to fund redemptions of certain existing notes, pay related fees and expenses, and support general corporate purposes.
  • The notes are senior unsecured obligations of Teva’s wholly owned financing subsidiaries and are guaranteed by Teva on a senior unsecured basis.

TEVA PHARMACEUTICAL INDUSTRIES LTD (NYSE: TEVA), through its wholly owned financing subsidiaries, issued $1,200,000,000 ($1.2 billion) of 5.250% senior notes due 2032 on September 16, 2026. Its wholly owned financing subsidiaries also issued €1,000,000,000 (€1 billion) of 4.250% notes due 2033, €500,000,000 of 4.625% notes due 2036, and two $1,000,000,000 ($1 billion) USD tranches due 2034 and 2037. The proceeds are intended to fund redemptions of certain existing notes, pay related fees and expenses, and support general corporate purposes with any remaining funds.

Five New Senior Note Tranches

Teva Pharmaceutical Finance Netherlands II B.V. Issued the two Euro Notes, while Teva Pharmaceutical Finance Netherlands III B.V. Issued the 2034 and 2037 USD Notes. Teva Pharmaceutical Finance Netherlands IV B.V. Issued the $1,200,000,000 2032 USD Notes. The 2033 Euro Notes carry a 4.250% coupon and mature in 2033. The 2036 Euro Notes carry a 4.625% coupon and mature in 2036. The USD Notes carry coupons of 5.250%, 5.500% and 5.750%, with maturities in 2032, 2034 and 2037, respectively. The Euro Notes and USD Notes are senior unsecured obligations of their respective financing subsidiaries. TEVA Pharmaceutical Industries Limited guarantees the notes on a senior unsecured basis.

Redemption Plans Cover Existing Debt

Teva may issue further Redemption notices, redeem other outstanding notes or change the principal amounts covered by existing notices.

Terms Include Early Redemption Rights

The applicable financing subsidiaries may redeem the new notes before maturity, subject to notice periods and the terms of their respective indentures. Redemption prices generally are set at the greater of 100% of principal or a discounted present-value amount, plus accrued and unpaid interest. For the USD Notes, the discount is based on the Treasury Rate plus 15 basis points for the 2034 USD Notes, 20 basis points for the 2037 USD Notes and 15 basis points for the 2032 USD Notes. The notes may also be subject to an offer to repurchase at 101% of principal following a change of control triggering event. The indentures restrict, subject to specified exceptions, certain liens, sale-leaseback transactions and mergers, consolidations or asset transfers. They also include customary events of default covering nonpayment, covenant breaches, certain other debt acceleration, guarantee enforceability and Bankruptcy or Insolvency events.